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Abstract 
Introduction: The ablation of supraventricular tachycardias (SVT) using radiofrequency en-
ergy (RF) is a procedure with a high primary success rate. However, there is a scarcity of 
data regarding the long term outcome, particularly with respect to quality of life (QoL).   
Methods and Results: In this retrospective single-center study, 454 patients who under-
went ablation of SVT between 2002 and 2007 received a detailed questionnaire addressing 
matters of QoL. The questionnaire was a modified version of the SF-36 Health Survey 
questionnaire and the Symptom Checklist – Frequency and Severity Scale.   
After a mean follow up of 4.5±1.3 years, 309 (68.1%) of the contacted 454 patients (269 
female, 59.2%, mean age 58+/-6.5) completed the questionnaire. Despite of 27% of relapses 
in the study group, 91.7% considered the procedure a long-term success. The remainder of 
patients experienced no change in (3.7%) or worsening of (4.7%) symptoms. There were no 
significant differences between the various types of SVT (p=1). QoL in patients with 
Atrio-Ventricular Nodal Reentry Tachycardia (AVNRT) and Atrio-Ventricular Reentry 
Tachycardia (AVRT) improved significantly (p<0.0005 respectively p<0.043), whereas QoL in 
patients with Ectopic Atrial Tachycardia (EAT) showed a non-significant trend towards im-
provement. Main symptoms before ablation, such as tachycardia (91.5%), increased incidence 
of tachycardia episodes over time (78.1%), anxiety (55.5%) and reduced physical capacity in 
daily life (52%) were significantly improved after ablation (p<0.0001).   
Conclusion: The high acute ablation success of SVT persists for years in long term follow up 
and translates into a significant improvement of QoL in most patients.   
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Introduction 
RF catheter ablation of SVT is a well-established 
treatment in invasive electrophysiology with a pri-
mary success rate of more than 90% in all substrates. 
SVT ablation specifically targets the electroanatomical 
substrate, such as the slow pathway in AVNRT, the 
accessory pathway in AVRT or an ectopic focus in 
EAT.  
Oftentimes, these specific SVT are difficult to 
treat medically due to therapy refractoriness. There-




due to its high primary success rate and low compli-
cation rate (1-6).  
Patients with paroxysmal SVT often present with 
symptoms like palpitations, dyspnea, fatigue, chest 
pain or worsening of heart failure under physical or 
emotional stress. Heart rates of 200 beats per minute 
and more are not uncommon, especially in young 
patients or in patients with AVRT and associated 
atrial fibrillation (AF). Recurrent syncope or other 
life-threatening complications like ventricular tachy-
cardia and/or ventricular fibrillation may occur.  
Due to the paroxysmal character of the tachy-
cardia, with sudden unexpected onset of symptoms, 
patients are limited in their daily life concerning 
work, social events and sports. Due to this nature of 
the disease QoL is increasingly impaired over time. 
Despite of the high immediate success rate of SVT 
catheter ablation, very little data is available con-
cerning the development of QoL in the long-term. The 
published literature mainly deals with the electro-
physiological long term results of RF ablation. So far, 
QoL before and after ablation has not been system-
atically investigated in these patients (7-13). In con-
trast, other SVT like atrial flutter and AF have been 
intensively investigated under this aspect (14-23).  
 
Methods 
Study population  
All patients included either had a typical history 
of a paroxysmal on-off tachycardia or documented 
narrow complex SVT pattern in a twelve lead ECG. 
They consecutively underwent an electrophysiologi-
cal study. If an AVNRT, AVRT or EAT could be in-
duced and ablated with primary success, patients 
were later selected for participation in this retrospec-
tive single-center study.  
All 454 patients, (59.2% female, 40.8% male, 
mean age 58 (+/- 16.5) years) who had undergone RF 
catheter ablation for AVNRT, AVRT or EAT at our 
institution between 2002 and 2007 were mailed a de-
tailed questionnaire. This questionnaire was a version 
of the SF-36 Health Survey questionnaire and the 
Symptom Checklist–Frequency and Severity Scale, 
modified to specifically reflect questions of QoL in 
SVT, enabling the authors to translate the various 
domains and components of well being into a quan-
titative value. 
For reasons of structure and to simplify an-
swering for the patients we divided the questionnaire 
in three different blocks: the first block was related to 
the situation for the patients before ablation, questions 
in the second block dealt with the situation during 
ablation and the third block exclusively applied to the 
post ablation period.  
The modified version of the SF-36 consists of a 36 
item questionnaire that assesses eight health concepts: 
general health perception, physical functioning, social 
functioning, role limitations due to physical problems, 
bodily pain, mental health, role limitations due to 
emotional problems, and vitality. In addition the 
SF-36 also generates physical and mental component 
summery scores. 
Irrespective of the well known shortcomings of 
the Symptom checklist because of the nonspecific 
nature of a number of the symptoms asked for and the 
lack of assessment of functional status the Symptom 
checklist is straightforward to use, sensitive to change, 
and has been utilized in a growing number of studies 
concerning arrhythmias. We asked for specific 
symptoms e.g. as tachycardia, palpitations, dyspnea, 
anxiety and angina pectoris.  
If no response had been received after 4 weeks, 
the patients were contacted by telephone and asked to 
participate. 309 (68.1%) of the contacted 454 patients 
fully completed the questionnaire. 145 (31.9%) pa-
tients had to be excluded due to incomplete or inco-
herent answers or because they completely failed to 
participate. Patients suffering from new palpitations 
and SVT were contacted for a second time and were 
asked to additionally submit a recent 12 lead ECG for 
analysis.  
Electrophysiological study and radiofrequency 
catheter ablation  
In all patients, a standard setting with four di-
agnostic catheters was used (high right atrium, HIS 
bundle region, right ventricular apex and coronary 
sinus). Before ablation, the underlying clinical tachy-
cardia had to be able to be repeatedly induced before 
detailed mapping and the ablation maneuvers were 
performed. The ablation itself was performed in sinus 
rhythm in most cases or under continuing tachycar-
dia, if so required for mapping.   
The ablation itself was performed using either an 
irrigated tip or a conventional tip ablation catheter. 
Successful ablation was defined as the 
non-reinducibility of the native tachycardia or the loss 
of the delta wave in AVRT. Subsequently, further 
electrophysiological testing for additional tachycar-
dias, which could potentially have been masked by 
the now ablated primary tachycardia, was performed. 
The aforementioned endpoints were re-evaluated 
after a waiting period of at least 20 minutes.  
Statistical Analysis 
For the description of the metric variables the 




viation (SDA) and extreme (minimum and maxi-
mum), quartile (25. and 75. percentile) and median. 
The distribution of categorical data is expressed by 
absolute and relative frequency.   
The comparison of the distribution of the cate-
gorical variables before and after ablation concerning 
two variables was expressed by the McNemar Test. 
More than two variables were compared using the 
Chi-square-distribution. For the comparison of the 
distribution of categorical and ordinal variables of 
independent random samplings we used Fisher’s ex-
act test. If the Gaussian distribution acceptation was 
declined, we used a non-parametric test for differ-
ences in groups the Mann Whitney U Test or the 
Kruskal-Wallis-Test, otherwise the t- or F-test.  
Results 
Study population 
309 (68.1%) patients were included into the 
study. In 230 of the 309 patients the SVT substrate was 
an AVNRT (74.4%), in 66 patients an AVRT (21.4%) 
and in 13 patients an EAT (4.2%). The distribution 
between the sexes (female/male) in AVNRT was 
62.2/37.8, in AVRT 50/50 and in EAT 53.9/46.2. Mean 
age was 58 (±16.5) for the whole study group, 62 
(±15.3) for AVNRT, 48 (±17.6) for AVRT and 63 (±13.3) 
for EAT. With respect to the underlying tachycardia, 
66.9% of patients with AVNRT, 75% of patients with 
AVRT and 59.1% of patients with EAT respectively 
submitted a fully completed questionnaire.   
Time to diagnosis, time to ablation, baseline data 
of ablation  
Regarding the time interval between the first 
occurrence of the tachycardia, its diagnosis and the 
year of ablation, we found significant differences. 
Regarding the whole study cohort, the underlying 
SVT was diagnosed 9.1±11.2 years (25%/75% percen-
tile – 1.0/15.0) and ablated 14.4±12.7 years (25%/75% 
percentile – 3.0/24.0) after the first episode of tachy-
cardia. These time intervals (time to diagnosis/time to 
ablation) differed between the specific SVT (Table 1). 
The time interval between the first occurrence of the 
tachycardia and the diagnosis in AVRT was therefore 
significantly shorter compared to the AVNRT patients 
(p<0.05); however, the earlier diagnosis of AVRT did 
not lead to earlier ablation as well.  
Baseline data of the ablation procedure compar-
ing the number of RF burns, the total examination 
time and the fluoroscopy duration are summarized in 
Table 1. There were no significant differences between 
the different types of SVT.  
Table 1: Baseline demographic characteristics and pro-
cedural findings in 309 patients with completed question-
naire.  
Patients   Numbers/percentage 
Patients included  309 – 68%  
Female  269 – 59% 
Male  185 – 41% 
AVNRT  230 – 74% 
AVRT  66 – 66%  
EAT  13 – 4% 
From symptom to diagnosis (Years)  Total – 25%/75% perc. 
All patients  9.1±11.2 – 1.0/15.0 
AVNRT  10.3±11.9 – 1.0/18.0 
AVRT  4.7±7.2 – 0.0/9.0 
EAT  7.5±8.7 – 0.0/18.0 
From symptom to ablation (Years)   
All patients  14.4±12.7 – 3.0/24 
AVNRT  15.0±13.3 – 3.0/25.0 
AVRT  12.3±10.0 – 3.0/20 
EAT  10.9±7.4 – 6.0/18.0 
RF-Applications (Number)   
All patients  7.3±6.7 – 3.0/8.5 
AVNRT  7.4±6.9 – 3.0/8.0 
AVRT  6.8±6.5 – 2.0/10 
EAT  8.0±3.6 – 6.0/9.0 
Examination time (Minutes)   
All patients  141.3±55.6 – 100/170 
AVNRT  134.3±52.4 – 96/160 
AVRT  156.1±58.7 – 117.5/193.5  
EAT  189.5±59.7 – 135/240 
Fluoroscop time (Minutes)   
All patients  19.0±13.9 – 10.8/22.8 
AVNRT  16.4±11.0 – 10.4/19.2 
AVRT  25.5±19.2 – 12.3/31.9 
EAT 
 
30.5±11.4 – 21.7/35.1 
 
 
Quality of life and specific symptoms due to 
tachycardia prior to ablation  
In the questionnaire, all patients were asked to 
state their symptoms and grade them on a severity 
scale. We inquired about the nature and quantity of 
tachycardia and the associated symptoms. Further-
more, the effect of symptoms on the patients` daily 
and social life, especially with respect to abstinence 
from work, sports and hobbies was surveyed.  
Patients were asked to assess the changes in 
daily and social life prior to the ablation procedure 
itself using a 5-level ranking scale (extreme, very 
strong, strong, moderate, low). In total, more than 
60% of the patients (178, 60.7%) stated a strong to ex-
treme impairment in daily life, whereas the rest of the 
patients (94, 29.3%) indicated only moderate or little 
changes due to the tachycardia. The detailed results 




Table 2: Distribution of symptoms prior to ablation for 
AVNRT-, AVRT-and EAT patients. Panel A: Quantity and 
duration of episodes and the associated symptoms. Panel 
B: Detraction in daily life generally and in parts of daily life.  
   AVNRT  AVRT  EAT 
variable  Value    N %  N %  N % 
PANAL A            
Extreme  27  12.5 6 9.2 6 46.1 
Very 
strong 
49 22.8  16 24.6 3  23.1 
Strong 57  26.5  13  20.0  1  7.7 
Moderate 46  21.4  10  15.4  2  15.4 
Low  26  12.1 9 13.9  1 7.7 
Detraction 
in daily life 
none 10  4.7  11  16.9  0  0 
Yes  5 20.0 19  38.0  1 11.1  Limited in 
Business/school  no 20  80.0  31  62.0  8  88.9 
Yes 33  22.8  16  30.2  1  10.0  Limited in 
sports  No 112  77.2  37  69.8  9  90.0 
Yes 35  31.3  21  48.8  2  18.2  Limited in 
hobbies  No 77  68.8  22  51.2  9  81.8 
Yes 39  30.2  20  48.8  2  18.2  Limited in  
Garden work  No 90  69.8  21  51.2  9  81.8 
Yes  4 16.0 18  43.9  2 20.0  Limited in  
Work at home  No 21  84.0  23  56.1  8  80.0 
Yes  8 38.1 20  52.6  0 0  Limited in 
Social life   No 13  61.9  18  47.4  9  100 
Yes  70  30.4 9 13.6  6 46.2  Limited in 
others  no 160  69.6  57  86.4  7  53.8 
PANAL B            
Extreme  27  12.5 6 9.2 6 46.1 
Very 
strong 
49 22.8  16 24.6 3  23.1 
Strong 57  26.5  13  20.0  1  7.7 
Moderate 46  21.4  10  15.4  2  15.4 
Low  26  12.1 9 13.9  1 7.7 
Detraction 
in daily life 
none 10  4.7  11  16.9  0  0 
Yes  5 20.0 19  38.0  1 11.1  Limited in 
Business/school  no 20  80.0  31  62.0  8  88.9 
Yes 33  22.8  16  30.2  1  10.0  Limited in 
sports  No 112  77.2  37  69.8  9  90.0 
Yes 35  31.3  21  48.8  2  18.2  Limited in 
hobbies  No 77  68.8  22  51.2  9  81.8 
Yes 39  30.2  20  48.8  2  18.2  Limited in  
Garden work  No 90  69.8  21  51.2  9  81.8 
Yes  4 16.0 18  43.9  2 20.0  Limited in  
Work at home  No 21  84.0  23  56.1  8  80.0 
Yes  8 38.1 20  52.6  0 0  Limited in 
Social life   No 13  61.9  18  47.4  9  100 
Yes  70  30.4 9 13.6  6 46.2  Limited in 
others  no 160  69.6  57  86.4  7  53.8 
 
 
Regarding the whole study population prior to 
ablation, 305 patients (99.0%) had specific symptoms. 
The main reasons for patients seeking therapy were 
tachycardic palpitations (281 patients, 91.5%) and 
increasing incidence of episodes (224 patients, 78.1%). 
In descending order, patients as well complained of 
anxiety (171 patients, 55.5%), reduced work capacity 
(164 pts., 53.3%), dyspnea (138 patients, 44.8%) and 
angina pectoris (137 patients, 44.5%). Symptoms such 
as palpitations (77 patients, 25%), ophthalmic fibrilla-
tion (70 pts., 22.7%) and syncope (47 patients, 15.4%) 
were relatively infrequent (Table 1, Figure 1). 
 
 
Figure 1: Symptoms leading patients to therapy: X-axis: 
Symptoms in declinary order. (1) Overall symptoms with-
out specification, (2) tachycardia, (3) increase of episodes 
over the years, (4) anxiety, (5) reduction in capacity, (6) 
dyspnea, (7) angina pectoris, (8) palpitations, (9) ophthalmic 
fibrillation, (10) syncope. Y-axis: percentage of patients 
presenting these symptom. 
 
Ablation success rate 
Independent of symptoms, the patients had to 
rate the perceived success of the ablation procedure in 
general (very successful, successful, moderately suc-
cessful or not successful). The majority of patients 
rated the ablation procedure “very successful” or 
“successful”. This is true for the whole study popula-
tion as well as for each SVT subgroup. Details are 
given in Figure 2.  
 
 
Figure 2: Satisfaction due to the ablation procedure. 
X-axis: (1) All patients, (2) AVNRT, (3) AVRT, (4) EAT. 
Pillars from left to right: very successful (black pillar), suc-
cessful (white pillar), moderate (dark grey), not successful 




Comparison of quality of life before and after 
ablation  
The general QoL and QoL with respect to the 
above mentioned symptoms were retrospectively 
evaluated before and after ablation. The aforemen-
tioned questionnaires included a section asking par-
ticipants to grade their well-being using a six-level 
ranking scale (very good (1), good (2), satisfactory (3), 
sufficient (4), defective (5) and insufficient (6)).   
Patients with AVNRT, AVRT and EAT rated 
their state of health before and after ablation. The 
changes within the ranking scale before and after ab-
lation is demonstrated in Figure 3.  
 
 
Figure 3: Comparison and improvement state of health before (black pillars) and after (white pillars) ablation. X-axis: State 
of health ranking scale from 1 to 6: very good (1), good (2), satisfactory (3), sufficient (4), defective (5) and insufficient (6). 
Y-axis: Percentage of patients Panel A: AVNRT. Panel B: AVRT. Panel C: EAT  
 
 
Comparing the categorical variables before and 
after ablation in AVNRT patients, applying the 
McNemar-Test we found a highly significant im-
provement with respect to state of health (p<0.0005) in 
this large patient group (Figure 3, Panel A). Regarding 
the single aspects of well-being, we found highly sig-
nificant improvements in daily (hobbies and work at 




life and participation in sports as well showed a trend 
towards improvement; however, this difference was 
not significant (p>0.05).  
Comparing the categorical variables in patients 
with AVRT before and after ablation applying the 
McNemar-Test, we found a significant improvement 
with respect to state of health (p<0.044) in this patient 
cohort (Figure 3, Panel B). Regarding the individual 
data, we found a highly significant improvement for 
all variables concerning daily and social life 
(p<0.0005).  
In patients with EAT a remarkable improvement 
in state of health was found. This difference was not 
significant (p<0.505). Analysis of data concerning in-
dividual symptoms were not accomplished because of 
the small patient cohort.  
Recurrent arrhythmias  
Recurrent arrhythmias were defined as relapse 
of the ablated tachycardia (true relapses), or the 
crossover to a new SVT like atrial flutter or AF. Figure 
4 demonstrates the relationship between true relapses 
and the crossover to a new SVT. In long term follow 
up, 219 patients (73%) of the whole study population 
deemed themselves completely free of SVT, whereas 
27% (81 pts.) stated to be suffering from recurrent 
tachycardia (AVNRT: 155 (69.8%) patients free of SVT, 
67 (30.2%) patients with relapse; AVRT: 56 (86.2%) 
versus 9 (13.8%) patients and EAT 8 (61.5%) versus 5 
(38.5%) patients).  
Bivariate analysis was performed to calculate if 
relapses were influenced by different types of vari-
ables, such as gender or age. Gender was found to not 
have a significant influence, this was true for the 
whole population and as well for patients with 
AVNRT or AVRT (Fischer`s exact test: All patients 
p=0.430, AVNRT p=0.552, AVRT p=0.149, EAT with 
too small a sample size). Age was as well found to not 
have a significant influence, this was true for the 
whole population and as well for patients with 
AVNRT or AVRT (Shapiro-Wilk-Test, 
Mann-Whitney-U-Test: All patients p=0.540, AVNRT 
p=0.179, AVRT p=0.352, EAT with too small a sample 
size).  
Multivariate analysis was performed applying a 
logistic regression analysis. None of the abovemen-
tioned factors was shown to have an influence on the 
frequency of relapses, neither for the whole study 
cohort nor for patients with AVNRT or AVRT. 
Concerning the patients with recurrent tachy-
cardias, there still was a non-significant trend towards 
better QoL. We detected significant improvement in 
the symptoms tachycardia and anxiety as well as an 
increase in work capacity (McNemar Test: p<0.0005, 




Figure 4: Recurrent arrhythmias dependent on true re-
lapses of the pre-existing native tachycardia ablated (dark 
pillar), or the crossover to a new SVT (bright pillar). X-axis: 
Relapses in all patients, patients with AVNRT, AVRT and 
EAT. Y-axis: Percentage of patients 
Discussion 
Background: The ablation of AVNRT, AVRT and 
EAT using RF energy has become the first line therapy 
for patients with recurrent episodes of these ar-
rhythmias. Acute and long term success with respect 
to the primary electrophysiological outcome has been 
very well documented (6, 9, 10, 20, 24).  
However, there are indications that, despite of 
successful primary ablation, new arrhythmias can 
arise in the long term (1, 2, 7). Data on QoL in short 
term follow-up after RF ablation of SVT is available 
from a few studies of smaller patient groups, but de-
spite of the large number of patients ablated world-
wide, there is a scarcity of data regarding the long 
term outcome, particularly with respect to QoL (8, 9, 
25). This is somewhat surprising, as atrial flutter and 
AF have been intensively investigated under this as-
pect (14-23). This is the first study on long term elec-
trophysiological outcome and its impact on the QoL 
in a large patient group.  
Study cohort: The number of patients lost in long 
term follow up is consistent with long-term surveys 
using written questionnaires (14, 19). A significant 
number of submitted questionnaires had to be ex-
cluded because they were not fully completed. This is 
most likely due to patients not being able to remem-
ber the initial symptoms after the relatively long fol-
low-up interval. We observed a linear increase in the 
proportions of sufficiently completed questionnaires 
over the time during which the ablations were per-




Regarding the patients reporting tachycardic 
palpitations during follow-up, we found only a low 
rate of recurrences of the original tachycardia and 
mainly a shift to new SVT. This corresponds with the 
findings of other series in which catheter ablation was 
performed with a high primary success rate (1, 7, 14,). 
The technical data of the ablation procedure as well as 
the primary and long-term electrophysiological suc-
cess rates are in line with the literature (1-6, 9, 10).  
Quality of life in long term follow-up: Prior to 
interventional therapy, patients mainly suffered from 
symptoms like tachycardia, increasing incidence of 
episodes over time, reduction in physical work ca-
pacity, dyspnea and angina pectoris. These symptoms 
were the main reasons why patients seeked treatment.   
More than 90% of the patients in each arrhyth-
mia subgroup described the procedure as successful 
in the long-term follow up. A highly significant im-
provement in QoL could be demonstrated in the ma-
jority of patients. More detailed analysis as well re-
vealed highly significant and sustained improvement 
in fundamental daily and social life, both for the 
whole study cohort and for the different types of SVT.  
In contrast, patients without ablation therapy 
and longstanding medical therapy suffer from side 
effects of medication as well as from recurrent epi-
sodes of SVT leading to reduced QoL (12). 
Recurrent arrhythmias: 27% of all patients suf-
fered from recurrent arrhythmias which, apart from 
AVRT patients, to the largest part were not relapses of 
the primary SVT, (Figure 4). This phenomenon has as 
well been observed by other groups (26, 27). Bi- and 
multivariate analysis of the data collected in this 
study did not identify independent predictive factors 
of arrhythmia recurrence. The data does not comprise 
information on total RF energy used; therefore, no 
statement with regards to its effect on arrhythmia 
recurrence can be made based on this study.  
Even if the patients developed a recurrent ar-
rhythmia, their QoL still measurably improved. Al-
though the total QoL-score only showed a 
non-significant trend towards improvement, various 
symptoms, such as tachycardia, anxiety and per-
formance capacity were significantly improved. Pre-
vious studies have suggested a causal relationship 
between different types of right inferior atrial SVT, 
such as common type atrial flutter and AVNRT, be-
cause of a possible shared pathway in the low right 
atrium, leading to an electrical modulation of atrial 
tissue substrate (28, 29, 30). A placebo effect as well 
might be responsible for the improvement in QoL in 
patients with recurrent arrhythmias.   
Study limitations  
There are some limitations to this study: First, 
the subjective benefit of an ablation procedure is 
complex. Various tools have been developed trying to 
translate the various domains and components of 
well-being into a quantitative value. We assessed the 
subjective benefit with a modified version of the SF-36 
Health Survey questionnaire and the Symptom 
Checklist – Frequency and Severity Scale. Although 
conclusions are clinically relevant, it still remains dif-
ficult to provide quantitative assessment of QoL. 
Second, since all patients had been willing to 
undergo an invasive procedure with potentially sig-
nificant adverse effects, this study group was highly 
motivated and highly selected. The perspective of a 
definitive treatment and ongoing medical surveillance 
after the procedure may have induced a perception 
bias in patients and have lead to overstatement of the 
perceived ablation success.   
Third, the potential negative impact of 
anti-arrhythmic drug therapy on QoL may have sig-
nificantly contributed to the low baseline scores, fur-
ther motivating patients to seek non-pharmacological 
therapy. The marked improvement in measurement 
of QoL may have been related to reduced symptoms 
from side effects after the discontinuation of 
anti-arrhythmic medication. Pharmacological treat-
ment was not studied in detail. Finally, the study was 
retrospective and the time interval between the abla-
tion procedure and the questionnaire was not uni-
form. Patients who had more recently undergone the 
procedure may therefore have had a different recol-
lection of symptoms than those having undergone the 
procedure at an earlier point of time. Therefore, pla-
cebo effects as well may have affected the perception 
of the patients of the success of the procedure and 
improvement in their QoL.  
Conclusions 
Patients with symptomatic arrhythmias treated 
with RF catheter ablation show significant reductions 
in arrhythmia-related symptoms and improvement in 
physical, emotional and social indexes of their 
health-related QoL. Self-imposed restrictions on 
physical and social activities are markedly reduced 
after catheter ablation. These improvements persist 
during long term follow up. Efforts should be made to 
increase awareness of symptoms and treatment op-
tions of SVT among patients and physicians, aiming at 
the elimination of delays in the process of symptom 





AVNRT: Atrio-Ventricular Nodal Reentry 
Tachycardia; AVRT:  Atrio-Ventricular Reentry 
Tachycardia; AF: Atrial Fibrillation; EAT: Ectopic 
Atrial Tachycardia; F:  French;  INR:  International 
Normalized Ratio; QoL: Quality of Life; RF: Radio 
Frequency; SDA: Standard Deviation; SVT: Su-
praventricular Tachycardia.  
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